title: Therapeutic drug monitoring in rheumatic  diseases: utile or futile?
abstract: Rapid and effective suppression of inflammation is a primary goal in the treatment of rheumatic diseases. However, the therapeutic effect of most medications may be slow to manifest, in the order of weeks or months in the case of DMARDs. Monitoring of drug concentrations allows the possibility of appropriate dose adjustment or changes in medication to achieve more rapid or better outcomes. We review the evidence for drug concentration monitoring. Despite the theoretical utility for monitoring of MTX polyglutamate concentrations in red blood cells in patients with RA, studies have not shown a clear association between concentrations and either efficacy or toxicity and routine measurement is not yet recommended. Small studies associating disease control with concentrations of anti-TNF therapies and anti-drug antibodies suggest that routine monitoring may be useful in the future. However, the data are not yet sufficient for this recommendation. With the use of allopurinol in gout, there is a putative therapeutic range for the active metabolite oxypurinol; however, adjusting the allopurinol dose to achieve a target urate concentration is likely to be most effective, and measuring oxypurinol may be best suited to assessing drug adherence. Although measuring thiopurine metabolite concentrations with AZA therapy has been shown to be useful in IBD, studies in rheumatic diseases have so far failed to confirm a useful association between concentrations and disease control or drug toxicity. Whole blood concentrations of HCQ have been associated with disease control in SLE and future studies may be able to determine a therapeutic range.
authors.forename: Lisa K
authors.initials: LK
authors.lastname: Stamp
authors.forename: Murray
authors.initials: M
authors.lastname: Barclay
mesh_terms: D000493:Allopurinol / Q000097:blood / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000097:blood* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy; D016903:Drug Monitoring / Q000379:methods*; D006074:Gout Suppressants / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000097:blood / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000097:blood* / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D006074:Gout Suppressants; D014409:Tumor Necrosis Factor-alpha; D000493:Allopurinol; D008727:Methotrexate